INNO-F1

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respec...

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

South Korean bio-health company HK inno.N announced on Monday that it has released the new drug K-CAB for gastroesophageal reflux disease (GERD) in ...

South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...

Personal space has become more important since the COVID-19 pandemic swept the world, and one South Korean-led industrial design company has develop...

South Korea's food and bio giant CJ CheilJedang Corp. on Sunday said it opened Inno Play, an office space for commercializing innovative ideas and d...

South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...

South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD). South Korea's pharmaceutical pr...

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...

South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...

South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...

HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...

South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal...

HK inno.N Corp. (inno.N), a pharmaceuticals unit of Kolmar Korea, drew a massive $25 billion from retail investors for its listing thanks to its s...

HK inno.N Corp. (inno.N), a pharmaceuticals unit of South Korea's Kolmar Korea, set the initial public offering price at the top end of the proposed...

South Korea's private equity firm STIC Investments Inc. is tipped to be one of the main beneficiaries of upcoming initial public offerings in the co...

HK inno.N Corp., a pharmaceuticals unit of South Korea's Kolmar Korea, is set to go public in early August at a valuation of around 2 trillion won (...

HK inno.N Corp. (inno.N), previously known as CJ Healthcare Co. and now a subsidiary of Kolmar Korea, has initiated the IPO process for listing with...